...
首页> 外文期刊>European journal of gastroenterology and hepatology >The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital
【24h】

The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital

机译:英国地区综合医院四十年来巴雷特食管监测的演变和结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

IntroductionWe present the long-term outcome of Barrett's oesophagus (BO) at a District General Hospital set against the increasing numbers of patients with gastro-oesophageal reflux disease (GORD).MethodsData were collected prospectively over 37 years. Comparison of GORD without Barrett's (NoBO) versus BO was performed from 1/1/1977 to 31/12/2001 when the NoBO database closed and outcomes of all cases of BO diagnosed until 31/12/2011 and followed up until 31/12/2013 have been reported.ResultsDuring the period 1977-2001 the number of GORD NoBO cases was 11610, and that of BO cases was 764 (6.2% of all GORD); total number of BO cases in 1977-2011 was 1468. NoBO patients were younger than BO patients: 52.2 versus 61.6 years. There was a male predominance in both groups: NoBO 55% and BO 62% (P<0.0001). The prevalence of oesophageal adenocarcinoma (OAC) was 87/1468 (5.9%) BO cases. Its incidence was 54/1381 (3.9%); the mean interval between the diagnosis of BO and incident OAC was 9 years (range 13 months-25.4 years); there was one OAC per 192 patient-years of follow-up (0.52% per year). Mortality was significantly lower in 37 patients under endoscopic surveillance at the time OAC was diagnosed (51 vs. 88% P=0.0141) partly because of older age and comorbidity of the other 17, in whom serial endoscopy was contraindicated. A proportional hazards model to allow for age estimated that the hazard rate ratio was lower in the surveillance group; however, this difference did not reach statistical significance (0.64, 95% confidence interval 0.30-1.48, P=0.08). Excluding prevalent cancers from both groups, mortality in BO was double that in NoBO (47 vs. 24%).ConclusionThese 37 years of observation suggest, but do not confirm, that endoscopic surveillance may reduce the risk of death from OAC. Modern technology is likely to yield better results, but larger prospective studies are needed to confirm the benefits.
机译:引言我们介绍了巴雷特食管(BO)在地区综合医院的长期结局,以应对越来越多的胃食管反流病(GORD)患者。方法前瞻性收集了37年的数据。自从1/1/1977到2001年12月31日进行了无Barrett's(BO)与BO的GORD的比较,当时NoBO数据库关闭并且所有BO病例的诊断结果一直持续到2011年12月31日,随后一直随访到31/12结果报告在/ 2013年。结果在1977-2001年期间,GORD NoBO病例数为11610,BO病例为764(占全部GORD的6.2%); 1977年至2011年,BO病例总数为1468例。NoBO病例比BO病例年轻:52.2岁对61.6岁。两组均以男性为主:NoBO 55%和BO 62%(P <0.0001)。食管腺癌(OAC)的患病率为87/1468 BO(5.9%)。其发生率为54/1381(3.9%); BO诊断和OAC事件之间的平均间隔为9年(范围为13个月至25。4年);每192个患者年的随访中有1个OAC(每年0.52%)。在诊断为OAC时,经内窥镜监测的37例患者的死亡率显着降低(51比88%,P = 0.0141),部分原因是年龄较大且其他17例合并症,而连续内镜是禁忌的。考虑到年龄的比例风险模型估计,监测组的风险比率较低;但是,这种差异并未达到统计学显著性(0.64,95%置信区间0.30-1.48,P = 0.08)。排除两组患癌率,BO的死亡率是NoBO的两倍(47%vs. 24%)。结论长达37年的观察表明,但未证实内镜监测可降低OAC致死的风险。现代技术可能会产生更好的结果,但是需要更大的前瞻性研究来证实其好处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号